Literature DB >> 29279817

Multi level statistical optimization of l-asparaginase from Bacillus subtilis VUVD001.

Rajeswara Reddy Erva1,2, T C Venkateswarulu2, Bangaraiah Pagala3.   

Abstract

Physical and chemical factors influencing the anti-leukemic l-asparaginase enzyme production by Bacillus subtilis VUVD001 were optimized using multi-stage optimization on the basis of preliminary experimental outcomes obtained by conventional one-factor-at-a-time approach using shake flasks. Process variables namely carbon, nitrogen sources, pH and temperature were taken into consideration during response surface methodology (RSM) optimization. The finest enzyme activity of 0.51 IUml-1 obtained by OFAT method was enhanced by 3.2 folds using RSM optimization. Artificial neural network (ANN) modelling and genetic algorithm (GA) based optimizations were further carried out to improve the enzyme drug yield. Results were also validated by conducting experiments at optimum conditions determined by RSM and GA optimization methods. The novel bacterium yielded in 2.88 IUml-1 of enzyme activity at optimum process variables determined by GA optimization, i.e., 0.5% glucose, 8.0% beef extract, 8.3 pH and 49.9 °C temperature. The study explored the optimized culture conditions for better yielding of anti-leukemic enzyme drug from a new bacterial source namely Bacillus subtilis VUVD001.

Entities:  

Keywords:  Artificial neural networks; Bioprocess optimization; Genetic algorithm; Statistical optimization methods; l-Asparaginase

Year:  2017        PMID: 29279817      PMCID: PMC5736497          DOI: 10.1007/s13205-017-1020-2

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  19 in total

1.  Stability of L-asparaginase: an enzyme used in leukemia treatment.

Authors:  A L Stecher; P M de Deus; I Polikarpov; J Abrahão-Neto
Journal:  Pharm Acta Helv       Date:  1999-12

Review 2.  Predictive non-linear modeling of complex data by artificial neural networks.

Authors:  Jonas S Almeida
Journal:  Curr Opin Biotechnol       Date:  2002-02       Impact factor: 9.740

3.  Studies on nutritional and oxygen requirements for production of L-asparaginase by Enterobacter aerogenes.

Authors:  J Mukherjee; S Majumdar; T Scheper
Journal:  Appl Microbiol Biotechnol       Date:  2000-02       Impact factor: 4.813

Review 4.  Pegaspargase: a review of clinical studies.

Authors:  Michael L Graham
Journal:  Adv Drug Deliv Rev       Date:  2003-09-26       Impact factor: 15.470

5.  Development of medium for enhanced production of glutaminase-free L-asparaginase from Pectobacterium carotovorum MTCC 1428.

Authors:  Sanjay Kumar; K Pakshirajan; V Venkata Dasu
Journal:  Appl Microbiol Biotechnol       Date:  2009-04-08       Impact factor: 4.813

Review 6.  L-asparaginase: a review.

Authors:  J C Wriston; T O Yellin
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1973

7.  L-asparaginase production by Erwinia aroideae.

Authors:  R E Peterson; A Ciegler
Journal:  Appl Microbiol       Date:  1969-07

Review 8.  Different methodologies for sustainability of optimization techniques used in submerged and solid state fermentation.

Authors:  Anup Ashok; Devarai Santhosh Kumar
Journal:  3 Biotech       Date:  2017-09-07       Impact factor: 2.406

Review 9.  L-asparaginase: a promising chemotherapeutic agent.

Authors:  Neelam Verma; Kuldeep Kumar; Gurnoor Kaur; Sneh Anand
Journal:  Crit Rev Biotechnol       Date:  2007 Jan-Mar       Impact factor: 8.429

10.  Isolation and screening of L-asparaginase free of glutaminase and urease from fungal sp.

Authors:  Kruthi Doriya; Devarai Santhosh Kumar
Journal:  3 Biotech       Date:  2016-11-12       Impact factor: 2.406

View more
  1 in total

1.  Computational modeling of culture media for enhanced production of fibrinolytic enzyme from marine bacterium Fictibacillus sp. strain SKA27 and in vitro evaluation of fibrinolytic activity.

Authors:  K Joji; A Santhiagu; Nisha Salim
Journal:  3 Biotech       Date:  2019-08-06       Impact factor: 2.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.